Revenue - Disaggregation of Revenue (Parenthetical) (Detail) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Total revenues		$ 9,294,000	$ 7,323,000
YUTIQ [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	[1]	4,611,000	3,029,000
YUTIQ [Member] | Ocumension Therapeutics [Member] | Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Total revenues		56,000	5,000
DEXYCU [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	[2]	4,399,000	3,773,000
DEXYCU [Member] | Ocumension Therapeutics [Member] | Supply Agreement [Member]
Disaggregation Of Revenue [Line Items]
Total revenues		$ 0	$ 0

[1] Included approximately $56 and $5 of revenue from YUTIQ product sales to Ocumension under a supply agreement for the three months ended March 31, 2022 and 2021, respectively.

[2] No revenue was recognized from DEXYCU product sales to Ocumension under a supply agreement for the three months ended March 31, 2022 and 2021.